Clinical trials: VZV
Bell's Palsy, Ramsay Hunt Syndrome
Safety and Effectiveness of the BlinkER System in Participants With Facial Nerve Palsy
Prospective, single-arm, multicenter, single-masked, pivotal study to Evaluate the Safety and Effectiveness of the Blinker system in Participants with Facial Nerve Palsy.
- Conditions
- Bell's Palsy, Ramsay Hunt Syndrome, Lyme Disease, Facial Palsy
- Trial name
- Paralysis (NCT06542289)
- Testing
- BlinkER device.
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Neurotrigger Ltd
Herpes Genitalis, Herpes Zoster
Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food
The objective of this study is to evaluate the safety and tolerability of single rising doses of ASP2151 under fasted condition in healthy male subjects.
- Trial name
- NCT02852876
- Testing
- ASP2151
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe Ltd.
Systemic Lupus Erythematosus
Zostavax in Systemic Lupus Erythematosus
Individuals with systemic lupus erythematosus (SLE, lupus) appear to be at increased risk for the development of shingles, a painful reactivation of the varicella zoster virus that causes chicken pox.
- Trial name
- NCT01474720
- Testing
- Zostavax vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Oklahoma Medical Research Foundation
Herpes Zoster, Shingles
ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
This study will describe the impact of vaccination with ZOSTAVAX™ on the epidemiology of herpes zoster (HZ) in a cohort of vaccinated participants 50 years or age or older, compared to a cohort of unvaccinated participants.
- Trial name
- NCT01600079
- Testing
- ZOSTAVAX™
- Volunteers
- 1,505,647 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014)
The study will evaluate the consistency of 3 lots of inactivated VZV vaccine for safety, tolerability, and immunogenicity in healthy adults.
- Trial name
- NCT02180295
- Testing
- V212 Lot 1, V212 Lot 2, V212 Lot 3
- Volunteers
- healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Varicella Zoster Virus Infection
VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination
To evaluate the effect of intramuscular RZV vaccine on VZV-specific skin TRM and circulating T-cells
- Trial name
- NCT04403139
- Testing
- Shingrix
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Washington
Shingles
Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)
The purpose of this study is to determine the immunity (the body's protection) against shingles after receiving two doses of an investigational vaccine or placebo (a look alike vaccine with no active ingredients).
- Trial name
- NCT00109122
- Testing
- zoster vaccine live (Oka/Merck)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Postherpetic Neuralgia
Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia
The purpose of this study is to evaluate the safety and efficacy of T-62 in subjects with postherpetic neuralgia.
- Trial name
- NCT00809679
- Testing
- T-62 Dose 1, T-62 Dose 2
- Where
- 13 sites in United States
- Volunteers
- 19 people
- Sponsor
- Pfizer
Immunity; Defect Due to Antibody or Cell Mediated Immune Defect
Cytokine Production and Immunity to Varicella Zoster Virus (VZV) in Elderly Recipients of Zoster Vaccine
After immunization, particularly in older persons, some people are protected from disease by a vaccine and others are not. The investigators believe that this variable response may be due to overproduction of molecules that…
- Trial name
- NCT01288014
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Columbia University
Measles, Mumps
Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)
This study will compare the safety, tolerability, and immunogenicity of measles, mumps, rubella, and varicella (MMRV) vaccine made with an alternative manufacturing process with those of the 2006 process
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT01536405
- Testing
- MMRV (AMP), MMRV (2006 process)
- Volunteers
- 1,412 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
Effective Study of Live Attenuated Varicella Vaccine to Treat Severe Resistant Psoriasis
Immunotherapy was reported in the treatment of psoriasis. Treatment of resistant psoriasis may be difficult and cyclosporine can induce some remission.
- Trial name
- NCT01356004
- Testing
- live attenuated chicken pox vaccine, saline, efficacy
- Where
- Egypt
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Cairo University
Neuropathic Pain
Comparison of 2 Vials of Components of a Synthetic Geranium Oil
The purpose of this study is to determine which component of an artificial geranium oil helps to reduce your neuropathy pain.
- Trial name
- NCT00611949
- Testing
- Geranium oil
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Pennington Biomedical Research Center
Peripheral Nervous System Diseases, Pain
Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
The purpose of the study is to assess the efficacy and safety of NGX-4010 applied for 60 minutes for the treatment of postherpetic neuralgia (PHN).
- Conditions
- Peripheral Nervous System Diseases, Pain, Neuralgia, Herpes Zoster
- Trial name
- NCT00115310
- Testing
- NGX-4010
- Volunteers
- 400 people
- Sponsor
- NeurogesX
Varicella
Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine
The objective of the study is as follows: 1. To know the antibody level during different interval after received 1 dose varicella vaccine. 2.
- Trial name
- NCT02146469
- Testing
- 2 doses with an 3 months interval, A second dose with an 1 year interval, A second dose with an 3 year interval
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Municipal Center for Disease Control and Prevention
Treatment of PHN
3VM1001 Cream for the Treatment of Pain Associated With Post Herpetic Neuralgia (PHN)
Post-herpetic neuralgia (PHN) is pain following acute herpes zoster; defined as pain lasting longer than 3 months. Current first line management consists of tricyclic anti-depressants and anti-convulsants such as gabapentin and…
- Trial name
- PHN (NCT03421613)
- Testing
- 3VM1001
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- CDA Research Group, Inc.
Herpes Zoster
Herpes Zoster Prevalence in Frailty Consultations
Herpes zoster and post herpetic pain are common causes of morbidity in the elderly. Herpes zoster is caused by reactivation of the virus varicella zoster of latent infection in sensory ganglia.
- Trial name
- NCT02832986
- Testing
- Medical Questionary
- Where
- France
- Volunteers
- 1,245 people
- Sponsor
- University Hospital, Toulouse
Herpes Zoster
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent…
- Trial name
- NCT05047770
- Testing
- HZ/su, Flu D-QIV, mRNA-1273
- Where
- 46 sites in United States
- Volunteers
- 2,013 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster, Pain
The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster
Postherpetic neuralgia (PHN) is the most common complication of herpes zoster (HZ) and represents a major clinical challenge due to its chronicity and impact on quality of life.
- Conditions
- Herpes Zoster, Pain, Postherpetic Neuralgia
- Trial name
- NCT07361796
- Testing
- Venlafaxine combined conventional therapy, Conventional therapy
- Where
- China
- Volunteers
- 832 people
- Sponsor
- Beijing Tiantan Hospital
Prevention of : Herpes-Zoster
Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)
Primary objective: Immunogenicity To demonstrate that a second dose of ZOSTAVAX® elicits higher varicella-zoster virus (VZV) antibody titres than a first dose of ZOSTAVAX® whether given as a 0-1 month schedule or as a 0-3 month…
- Trial name
- NCT00561080
- Testing
- Zostavax
- Volunteers
- 759 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the Boostrix® vaccine in adults aged 50 years or older compared to…
- Trial name
- NCT02052596
- Testing
- Herpes Zoster vaccine GSK 1437173A, Boostrix
- Where
- 13 sites in United States
- Volunteers
- 935 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline